Treatment of Psoriatic Arthritis with ≥5 Swollen Joints or Poor Prognostic Factors
Not all peripheral psoriatic arthritis follows the same management path. Patients presenting with five or more swollen joints — or with fewer joints alongside specific high-risk features — require prompt, structured intervention to protect joints and reach clinical targets.
Clinical Scenario
This protocol addresses peripheral psoriatic arthritis in patients with:
- Polyarthritis — ≥5 swollen joints, or
- Monoarthritis or oligoarthritis with poor prognostic factors, such as structural damage, elevated acute phase reactants, dactylitis, or nail involvement
Treatment Approach
In this setting, rapid initiation of a conventional synthetic DMARD (csDMARD) is recommended. Which option within this class is most appropriate may depend on whether clinically relevant skin involvement is also present — the full selection rationale and sequencing are in the structured protocol.
Treatment Targets
- At least 50% reduction in disease activity within 3 months
- Remission or low disease activity at 6 months
References
DOI: 10.1136/ard-2024-225531
In patients with polyarthritis, or those with monoarthritis/oligoarthritis and poor prognostic factors (eg, structural damage, elevated acute phase reactants, dactylitis or nail involvement), a csDMARD should be initiated rapidly, with methotrexate preferred in those with clinically relevant skin involvement.
Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.
Since the EULAR recommendations adhere to a treat-to-target (T2T) approach which implies a reduction of disease activity by at least 50% within 3 months and reaching the treatment target within 6 months, a csDMARD should not be continued if these therapeutic goals are not attained.
View source ↗